Abstract |
Anti- tumor efficacy of Gatipotuzumab, a therapeutic antibody targeting Tumor-Associated Mucin-1 (TA-MUC1), in relapsed ovarian cancer (OC) appeared to be rather heterogeneous. Whether adding a second anti-neoplastic drug may augment response towards Gatipotuzumab, has not been elucidated so far. Since it is known that anti-MUC1 antibodies may alter estrogen receptor activity in breast cancer, this potential interplay was investigated in OC. The correlation between TA-MUC1, estrogen receptors (ERs) and another 12 protein markers as well as their correlation with clinico-pathological parameters in 138 ovarian cancer cases was studied. Finally, Gatipotuzumab and 4-Hydroxy-TTamoxifen (4-OHT) as well as the combination of both was tested for its impact on cell viability in COV318, OV-90, OVCAR-3, and SKOV-3 cells. A strong positive correlation between TA-MUC1 and ERs was detected in OC tissue. Those cases missing ERs but staining positive for TA-MUC1 had significantly reduced overall survival. The combination of 4-OHT and Gatipotuzumab significantly reduced cell viability and was more effective than treatment with Gatipotuzumab alone. Co-stimulation with Gatipotuzumab enhanced the efficacy of 4-OHT in OVCAR-3 and SKOV-3. The data suggest an interplay of TA-MUC1 and ERs in OC. Whether the combination of Gatipotuzumab and TTamoxifen may enhance efficacy of either of the two drugs in vivo, or may even translate into a clinically relevant benefit over the respective monotherapies, remains to be investigated.
|
Authors | Sabine Heublein, Sabina Page, Doris Mayr, Elisa Schmoeckel, Fabian Trillsch, Frederik Marmé, Sven Mahner, Udo Jeschke, Aurelia Vattai |
Journal | International journal of molecular sciences
(Int J Mol Sci)
Vol. 20
Issue 2
(Jan 12 2019)
ISSN: 1422-0067 [Electronic] Switzerland |
PMID | 30642093
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Epitopes
- MUC1 protein, human
- Mucin-1
- PankoMab-GEX
- Receptors, Estrogen
- Tamoxifen
- afimoxifene
|
Topics |
- Antibodies, Monoclonal, Humanized
(chemistry, pharmacology)
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology)
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Cell Survival
(drug effects)
- Epitopes
(immunology)
- Female
- Humans
- Mucin-1
(chemistry, immunology)
- Ovarian Neoplasms
(drug therapy, metabolism)
- Receptors, Estrogen
(metabolism)
- Tamoxifen
(analogs & derivatives, pharmacology)
|